IDBS And ChemAxon Ltd. Partnership Extends To Harness Leading Biomolecule Handling Technology
Strategic technology deal strengthens IDBS’ single R&D data management platform
London, UK, Budapest, Hungary & Boston, US, February 22, 2017 – Today, IDBS announces that the strategic technology partnership with ChemAxon has been further strengthened. IDBS is now able to leverage ChemAxon’s Biomolecule Toolkit and BioEddie with its flagship E-WorkBook suite. The addition of the advanced biomolecule structure indexing and web rendering capabilities from ChemAxon complements IDBS’ deep-domain biology expertise and bolsters its single, cross-domain platform.
Paul Denny-Gouldson, Vice President, Strategic Solutions at IDBS said, “ChemAxon is a dynamic and innovative, scientific software provider. They have developed the Biomolecule Toolkit and drawing components very rapidly and we are extremely pleased we can leverage those in our web-based E-WorkBook R&D data management platform, which can be deployed both in the Cloud and on-premise. The industry has been demanding this type of capability for a long time and it is now being realized. Integrating it with E-WorkBook will enable scientists to capture and search all aspects of their biomolecule structural properties. We already capture and search everything else about biomolecules R&D in E-WorkBook but the structural information is the final piece of the puzzle”.
ChemAxon’s Biomolecule Toolkit stores all structural and non-structural information about complex biological entities and makes it searchable. BioEddie is an intuitive web-based biomolecule drawing package that enables biologists to define and visualize their molecules – something the chemistry world has been doing for decades. The Biomolecule Toolkit is also used as the foundation for a Biomolecule Registration solution supplied by ChemAxon – closing the gap again with the small molecule world. E-WorkBook will have an out-of-the-box interface with the ChemAxon Biomolecule registration solution.
“ChemAxon is always focused on its users’ scientific needs. This is why we could create an entire world of software solutions relying on our robust small molecule handling. Many of our customers, however, applied our tools to manage large biomolecules, which they of course were not readily designed for. Setting out to improve our abilities got us involved in the Pistoia Alliance HELM project, aimed at delivering a common language to describe complex biomolecules. The release of our Biomolecule Toolkit and its biomolecule drawing component, BioEddie, marks a milestone of ChemAxon being able to natively support biomolecules in our solutions.” said Dr Ferenc Csizmadia, CEO, ChemAxon. “IDBS’ E-WorkBook is a great platform to channel our knowledge into. Within the web environment users can easily zoom back and forth between sequence and atomic level. This opens up unprecedented ways of capturing biomolecule research activities, which will provide us novel use cases enabling us to further develop our and IDBS’ solution.”
IDBS and ChemAxon have been working on this innovative concept for some time. A handful of customers have already seen the first parts of ChemAxon’s technologies integrated in E-WorkBook when it was shown at the first joint IDBS & ChemAxon Biomolecule Forum, held in Boston during the ChemAxon UGM in September 2016. The feedback from this joint event was very positive and is now driving this innovative solution forwards. For more information on the technology partnership please contact Paul Denny-Gouldson pdgouldson@idbs.com IDBS or Roland Knispel rknispel@chemaxon.com ChemAxon.
-Ends-
About ChemAxon
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. We focus on active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA and sales and support offices in Europe, Japan and across North America.
For further information, please visit www.chemaxon.com or follow us on Twitter @chemaxon.
About IDBS
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data. Our technology and domain expertise enable users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS remains a privately held company employing over 250 staff across the world and serving over 50,000 researchers in 25 countries – including over 75% of the top twenty pharmaceutical companies.
For more information, please visit www.idbs.com or follow us on Twitter
London, UK, Budapest, Hungary & Boston, US, February 22, 2017 – Today, IDBS announces that the strategic technology partnership with ChemAxon has been further strengthened. IDBS is now able to leverage ChemAxon’s Biomolecule Toolkit and BioEddie with its flagship E-WorkBook suite. The addition of the advanced biomolecule structure indexing and web rendering capabilities from ChemAxon complements IDBS’ deep-domain biology expertise and bolsters its single, cross-domain platform.
Paul Denny-Gouldson, Vice President, Strategic Solutions at IDBS said, “ChemAxon is a dynamic and innovative, scientific software provider. They have developed the Biomolecule Toolkit and drawing components very rapidly and we are extremely pleased we can leverage those in our web-based E-WorkBook R&D data management platform, which can be deployed both in the Cloud and on-premise. The industry has been demanding this type of capability for a long time and it is now being realized. Integrating it with E-WorkBook will enable scientists to capture and search all aspects of their biomolecule structural properties. We already capture and search everything else about biomolecules R&D in E-WorkBook but the structural information is the final piece of the puzzle”.
ChemAxon’s Biomolecule Toolkit stores all structural and non-structural information about complex biological entities and makes it searchable. BioEddie is an intuitive web-based biomolecule drawing package that enables biologists to define and visualize their molecules – something the chemistry world has been doing for decades. The Biomolecule Toolkit is also used as the foundation for a Biomolecule Registration solution supplied by ChemAxon – closing the gap again with the small molecule world. E-WorkBook will have an out-of-the-box interface with the ChemAxon Biomolecule registration solution.
“ChemAxon is always focused on its users’ scientific needs. This is why we could create an entire world of software solutions relying on our robust small molecule handling. Many of our customers, however, applied our tools to manage large biomolecules, which they of course were not readily designed for. Setting out to improve our abilities got us involved in the Pistoia Alliance HELM project, aimed at delivering a common language to describe complex biomolecules. The release of our Biomolecule Toolkit and its biomolecule drawing component, BioEddie, marks a milestone of ChemAxon being able to natively support biomolecules in our solutions.” said Dr Ferenc Csizmadia, CEO, ChemAxon. “IDBS’ E-WorkBook is a great platform to channel our knowledge into. Within the web environment users can easily zoom back and forth between sequence and atomic level. This opens up unprecedented ways of capturing biomolecule research activities, which will provide us novel use cases enabling us to further develop our and IDBS’ solution.”
IDBS and ChemAxon have been working on this innovative concept for some time. A handful of customers have already seen the first parts of ChemAxon’s technologies integrated in E-WorkBook when it was shown at the first joint IDBS & ChemAxon Biomolecule Forum, held in Boston during the ChemAxon UGM in September 2016. The feedback from this joint event was very positive and is now driving this innovative solution forwards. For more information on the technology partnership please contact Paul Denny-Gouldson pdgouldson@idbs.com IDBS or Roland Knispel rknispel@chemaxon.com ChemAxon.
-Ends-
About ChemAxon
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. We focus on active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA and sales and support offices in Europe, Japan and across North America.
For further information, please visit www.chemaxon.com or follow us on Twitter @chemaxon.
About IDBS
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data. Our technology and domain expertise enable users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS remains a privately held company employing over 250 staff across the world and serving over 50,000 researchers in 25 countries – including over 75% of the top twenty pharmaceutical companies.
For more information, please visit www.idbs.com or follow us on Twitter